ASX-173

• Target:

  CDK|||ATG|||Autophagy|||Apoptosis|||Akt|||PARP|||Caspase

• Related Pathways:

  Apoptosis|||Cell Cycle/Checkpoint|||Autophagy|||Cytoskeletal Signaling|||Proteases/Proteasome|||PI3K/Akt/mTOR signaling|||DNA Damage/DNA Repair|||Chromatin/Epigenetic

• Bioactivity:

  ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 ?M and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase) . When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.

• Smiles:

  C(NC(C1=CC=CC=C1)C2=CC=CC=C2)(=O)[C@@H]3N(C([C@H](CC)N)=O)C[C@H]([C@@H]3O)C4=CC=C(F)C=C4

• Molecular Formula:

  C28H30FN3O3

• Molecular Weight:

  475.56

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  2748800-08-8